Serum Institute Invests in Needle-Free Injection Technology

Serum Organization of India (SII), the world’s driving immunization maker, has reported an essential interest in IntegriMedical. This coordinated effort expects to propel sans needle infusion innovation, possibly changing medical services conveyance.

Shared Vision for Improved Healthcare

The investment aligns with SII’s vision of “Health for All” and IntegriMedical’s mission to “Transform Healthcare Globally.” The partnership focuses on patient comfort, increased treatment adherence, reduced needle-stick injuries, and improved medication delivery through a needle-free approach.

Introducing the Needle-Free Injection System

IntegriMedical has developed a US-patented Needle-Free Injection System (N-FIS) that utilizes a high-powered jet stream to administer medications effectively. This innovative technology aims to eliminate injection pain, creating a more pleasant experience for patients with needle phobia.

Leaders Express Optimism

“At SII, we actively invest in technologies that make healthcare accessible and affordable globally,” stated Adar Poonawalla, CEO of SII. “IntegriMedical’s N-FIS represents a significant leap forward in drug delivery, and we envision a future where vaccines are administered without needles.”

Poonawalla further emphasized the potential impact on vaccinations: “This technology could revolutionize how we administer vaccines, making the process more comfortable for both patients and healthcare professionals.”

Sarvesh Mutha, MD of IntegriMedical, expressed his enthusiasm for the collaboration. “We are thrilled to have SII as our strategic partner,” he said. “This investment validates the potential of our N-FIS technology to revolutionize drug delivery. SII’s expertise in vaccine manufacturing and global distribution will be invaluable as we strive to make this technology accessible to patients worldwide.”

Regulatory Approvals and Innovation

IntegriMedical’s N-FIS has gotten administrative endorsements from CDSCO, CE, and MDSAP, and is ISO 13485 affirmed. Furthermore, the innovation is licensed in the US. Ankur Naik, MD at IntegriMedical, assumed a significant part in creating and testing N-FIS, showing its viability in decreasing torment and reducing needle fear.

Combining Expertise for Global Impact

The partnership between SII and IntegriMedical leverages the strengths of both entities. SII contributes its vast experience in vaccine production and global distribution networks, while IntegriMedical brings its innovative drug delivery technology and research capabilities. Together, they aim to expand access to healthcare and improve efficiency within the global healthcare system.

Initial Availability and Potential Benefits

N-FIS will initially be available in India’s private healthcare sector, offering patients and healthcare providers an alternative to traditional needle-based injections. This technology holds promise for eliminating needle phobia, reducing injection pain, simplifying administration, and preventing needle-stick injuries and cross-contamination.